Seeding Seedling

The Massachusetts-based Seedling Enterprises Inc. works with inventors who have ideas but don't know how to make them commercially viable. It selects the most promising ones, develops them, and, rather than forming a company, shops them around to potential device acquirers. Venture capitalists typically aren't interested because their targeted markets are too small. While the products may be niche, the returns, theoretically, can be pretty good--almost as good as VC returns, says co-founder Josh Tolkoff.

With venture capital firms increasingly interested only in device start-ups aimed at hundred-million-dollar or more markets, finding backers for new technologies with smaller applications is almost impossible. The problem is that venture capitalists can't exit niche companies—recent IPO markets have been brutal to young companies with demonstrated double-digit sales, let alone those with smaller targets. And, potential acquirers, the big device companies who continually need new products to replenish their portfolios, aren't necessarily willing to pay for a whole company just to get a narrow technology. While they once offered premiums on the expectation they'd derive synergies from such an acquisition, they are no longer as eager to do so.

At least that's the perception of several entrepreneurs who have in the past year started medical device incubators to develop raw material into commercially acceptable products and then sell those...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By 

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

More from Business

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.